These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8750045)

  • 1. Haloperidol does not affect the level of serum-soluble interleukin-2 receptor in drug-free male schizophrenics.
    Kim CE; Kang DY; Ha KS; Jeong SH; Kim YS
    Biol Psychiatry; 1995 Dec; 38(12):843-5. PubMed ID: 8750045
    [No Abstract]   [Full Text] [Related]  

  • 2. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cognition and driving in schizophrenic patients under treatment with risperidone vs. haloperidol].
    Dittert S; Soyka M; Winter C; Möller HJ
    Fortschr Neurol Psychiatr; 1999 Nov; Suppl 2():S70-3. PubMed ID: 10598340
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation].
    Vanelle JM; Amorim P; Piketti ML; Bourdel MC; Poirier-Littré MF
    Encephale; 1996 Oct; 22 Spec No 3():82-4. PubMed ID: 8954284
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessing a drug's cost-benefits.
    Raleigh F
    Psychiatr Serv; 1996 Aug; 47(8):877-8. PubMed ID: 8837167
    [No Abstract]   [Full Text] [Related]  

  • 6. Aripiprazole: novelty, adherence and understatement.
    Fear C
    Int J Neuropsychopharmacol; 2005 Mar; 8(1):131. PubMed ID: 15469664
    [No Abstract]   [Full Text] [Related]  

  • 7. [Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
    Barnas C; Stuppäck CH; Miller C; Haring C; Sperner-Unterweger B; Fleischhacker WW
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():36-40. PubMed ID: 1683338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics.
    Chin CN; Hamid AR; Philip G; Ramlee T; Mahmud M; Zulkifli G; Loh CC; Zakariah MS; Norhamidah MS; Suraya Y; Roslan KA; Chandramohan P; Cheah YC; Leonard AO
    Med J Malaysia; 1998 Dec; 53(4):365-71. PubMed ID: 10971979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients.
    Lahdelma RL; Appelberg B; Kuoppasalmi K; Katila H; Rimón R
    Eur Neuropsychopharmacol; 1991 Dec; 1(4):535-40. PubMed ID: 1688013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does a glutamate receptor blocker (Caroverine) enhance haloperidol in the treatment of schizophrenia?
    König P; Conca A; Lugmayer B
    Neuropsychobiology; 1999 Sep; 40(3):140-1. PubMed ID: 10494049
    [No Abstract]   [Full Text] [Related]  

  • 12. Depressive symptoms and schizophrenia a psychopharmacological approach.
    Mauri MC; Bravin S; Fabiano L; Vanni S; Boscati L; Invernizzi G
    Encephale; 1995; 21(5):555-8. PubMed ID: 8529564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic effects on serine and glycine metabolism.
    Baruah S; Waziri R; Sherman A
    Biol Psychiatry; 1993 Oct; 34(8):544-50. PubMed ID: 7903868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I and type II schizophrenia: relations between tonic electrodermal activity and clinical ratings before and after haloperidol treatment.
    Maina G; Barzega G; Bellino S; Bogetto F; Ravizza L
    Psychiatry Res; 1995 Jun; 57(1):49-56. PubMed ID: 7568558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study.
    Zhang XY; Zhou DF; Cao LY; Wu GY; Shen YC
    J Clin Psychopharmacol; 2006 Feb; 26(1):103-5. PubMed ID: 16415724
    [No Abstract]   [Full Text] [Related]  

  • 16. Longterm maintenance therapy with depot haloperidol in schizophrenia.
    Zbytovský J
    Homeost Health Dis; 1991; 33(5-6):287. PubMed ID: 18265499
    [No Abstract]   [Full Text] [Related]  

  • 17. ERPs in schizophrenia: effects of antipsychotic medication.
    Ford JM; White PM; Csernansky JG; Faustman WO; Roth WT; Pfefferbaum A
    Biol Psychiatry; 1994 Aug; 36(3):153-70. PubMed ID: 7948453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine.
    White K; Busk J; Eaton E; Gomez G; Razani J; Sloane RB
    Int Pharmacopsychiatry; 1981; 16(1):34-8. PubMed ID: 6117536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antipsychotic drugs on memory functions of schizophrenic patients.
    Eitan N; Levin Y; Ben-Artzi E; Levy A; Neumann M
    Acta Psychiatr Scand; 1992 Jan; 85(1):74-6. PubMed ID: 1347670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
    Arvanitis LA; Miller BG
    Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.